Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02381691
Other study ID # 2012-11
Secondary ID RC12_36302012-A0
Status Active, not recruiting
Phase N/A
First received February 4, 2015
Last updated September 29, 2015
Start date January 2013

Study information

Verified date September 2015
Source Assistance Publique Hopitaux De Marseille
Contact n/a
Is FDA regulated No
Health authority France: Agence Nationale de Sécurité du Médicament et des produits de santé
Study type Interventional

Clinical Trial Summary

Objective : To assess the analgesic effect of maternal breast milk odor in preterm neonates Design : A prospective, randomised, controlled, double blinded, monocentric trial.

Méthods : The neonates were included from 01/01/2012 to 31/12/2014. Inclusion criteria were: neonates fed with their mother breast milk, gestational age between 30 weeks of amenorrhea and 36 weeks + 6 days, a postnatal age ≤ 10 days and a birth weight greater than the 5th percentile according to Olsen curves et al. They also had to be: clinically stable, with 48 hours withdrawal of nasal CPAP, without administration of any analgesic or sedative drug in the last 48 hours and without any underlying disease. The two legal representatives must have signed an informed consent. The study excluded the neonates for whom no video was recorded during the venipuncture.

In the first group "breast milk", venipuncture was performed to the neonate while his mother's milk odor was being diffused. In a second control group, the same gesture was made with an odorless diffusor. The primary outcome was the clinical score assessment PIPP (Premature Infant Pain Profile). The secondary outcomes were the DAN score (Acute Pain of Newborn) and the salivary cortisol level.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 60
Est. completion date
Est. primary completion date January 2016
Accepts healthy volunteers No
Gender Both
Age group N/A to 10 Days
Eligibility Inclusion Criteria:

- neonates fed with their mother breast milk,

- gestational age between 30 weeks of amenorrhea and 36 weeks + 6 days,

- postnatal age = 10 days

- birth weight greater than the 5th percentile according to Olsen curves et al.

- clinically stable, with 48 hours withdrawal of nasal CPAP, without administration of any analgesic or sedative drug in the last 48 hours and without any underlying disease

- the two legal representatives must have signed an informed consent.

Exclusion Criteria:

- neonates for whom no video was recorded during the venipuncture

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care


Related Conditions & MeSH terms


Intervention

Other:
maternal breast milk odor

no odor


Locations

Country Name City State
France Assistance Publique des Hopitaux de Marseille Marseille

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique Hopitaux De Marseille

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary clinical score assessment PIPP (Premature Infant Pain Profile) 20 minutes No
Secondary DAN score (Acute Pain of Newborn) 20 minutes No
Secondary salivary cortisol level 20 minutes No